sHB-7192
AN ACT IMPLEMENTING RECOMMENDATIONS OF THE
BIPARTISAN DRUG TASK FORCE.

OFA Fiscal Note

State Impact:

Agency Affected	Fund-Effect	FY 26 $	FY 27 $
Treasurer, Debt Serv.	GF - Potential Cost	See Below	See Below

Note: GF=General Fund

Municipal Impact: None

Explanation

The bill makes various prescription drug and health care related changes which are noted below.

Sections 1 - 4 make numerous changes that result in no fiscal impact to the Insurance Department. The bill makes several changes regarding pharmacy benefits managers (PBMs) and rebate practices of health carriers, and health carrier reporting on these topics. No fiscal impact is expected, as the department does not anticipate a meaningful increase in workload and compliance by PBMs and health carriers is expected.

Section 5 establishes a task force to study emergency preparedness and mitigation strategies for prescription drug shortages resulting in no fiscal impact to the state because the task force has the expertise to meet the requirements of the bill.

Section 6 expands the Strategic Supply Chain Initiative program, which is funded by General Obligation (GO) bond funds, to include efforts to prevent or mitigate prescription drug shortages.

Primary Analyst: EW   5/12/25
 Contributing Analyst(s):
Reviewer: MM

Future General Fund debt service costs may be incurred sooner under the bill to the degree that it causes authorized GO bond funds to be expended more rapidly than they otherwise would have been.

As of May 1, 2025, there is $25 million in previously allocated bond funds from the Manufacturing Assistance Act program that have been set aside by the Department of Economic and Community Development to fund the Strategic Supply Chain Initiative program.

The bill does not change GO bond authorizations relevant to the program.

The Out Years

The annualized ongoing fiscal impact identified above would continue into the future subject to the terms of any bonds issued.